DE69942009D1 - Verbindungen für die behandlung von gewichtsverlust - Google Patents
Verbindungen für die behandlung von gewichtsverlustInfo
- Publication number
- DE69942009D1 DE69942009D1 DE69942009T DE69942009T DE69942009D1 DE 69942009 D1 DE69942009 D1 DE 69942009D1 DE 69942009 T DE69942009 T DE 69942009T DE 69942009 T DE69942009 T DE 69942009T DE 69942009 D1 DE69942009 D1 DE 69942009D1
- Authority
- DE
- Germany
- Prior art keywords
- patient
- receptor antagonist
- weight loss
- inhibitor
- administering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9822458.7A GB9822458D0 (en) | 1998-10-15 | 1998-10-15 | Methods of treatment |
GBGB9822459.5A GB9822459D0 (en) | 1998-10-15 | 1998-10-15 | Method of treatment |
GBGB9917181.1A GB9917181D0 (en) | 1999-07-23 | 1999-07-23 | Methods of treatment |
PCT/GB1999/003302 WO2000021509A2 (en) | 1998-10-15 | 1999-10-15 | Methods of treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
DE69942009D1 true DE69942009D1 (de) | 2010-03-25 |
Family
ID=27269516
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69942009T Expired - Lifetime DE69942009D1 (de) | 1998-10-15 | 1999-10-15 | Verbindungen für die behandlung von gewichtsverlust |
Country Status (9)
Country | Link |
---|---|
US (2) | US7417038B1 (de) |
EP (1) | EP1121111B1 (de) |
JP (1) | JP2002527378A (de) |
AT (1) | ATE457169T1 (de) |
CY (1) | CY1110282T1 (de) |
DE (1) | DE69942009D1 (de) |
DK (1) | DK1121111T3 (de) |
PT (1) | PT1121111E (de) |
WO (1) | WO2000021509A2 (de) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1121111E (pt) * | 1998-10-15 | 2010-05-17 | Imp Innovations Ltd | Compostos para o tratamento de perda de peso |
US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
GB0219660D0 (en) | 2002-08-23 | 2002-10-02 | Astrazeneca Ab | Therapeutic use |
US20040122067A1 (en) * | 2002-12-20 | 2004-06-24 | Lin Zhao | Treatment of chronic heart failure |
CA2551037A1 (en) | 2003-09-22 | 2005-03-31 | Banyu Pharmaceutical Co., Ltd. | Novel piperidine derivative |
AU2004294714B2 (en) | 2003-12-02 | 2009-12-10 | Ucb Pharma Gmbh | Novel use of peptide compounds for treating central neuropathic pain |
GB0403744D0 (en) | 2004-02-20 | 2004-03-24 | Astrazeneca Ab | Chemical process |
EP2305352A1 (de) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | 5-alpha-Reduktaseinhibitoren zur Behandlung von Stoffwechsel- und anthropometrischen Störungen |
EP1604655A1 (de) | 2004-06-09 | 2005-12-14 | Schwarz Pharma Ag | Neue Verwendung von Peptidverbindungen zur Behandlung von Trigeminusneuralgie |
WO2006020959A2 (en) | 2004-08-13 | 2006-02-23 | Amgen Inc. | Substituted benzofused heterocycles |
US7528175B2 (en) * | 2004-10-08 | 2009-05-05 | Inverseon, Inc. | Method of treating airway diseases with beta-adrenergic inverse agonists |
EP2127676A3 (de) | 2004-11-01 | 2013-09-04 | Amylin Pharmaceuticals, LLC | Behandlung von Fettleibigkeit und mit Fettleibigkeit zusammenhängenden Erkrankungen und Störungen |
US20090286723A1 (en) | 2005-02-11 | 2009-11-19 | Amylin Pharmaceuticals, Inc. | Hybrid Polypeptides with Selectable Properties |
US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
NZ562766A (en) | 2005-05-30 | 2011-03-31 | Banyu Pharma Co Ltd | Piperidine derivatives as histamine-H3 receptor antagonists |
US20100216758A1 (en) | 2005-08-10 | 2010-08-26 | Makoto Ando | Pyridone Compounds |
BRPI0614649A2 (pt) | 2005-08-11 | 2011-04-12 | Amylin Pharmaceuticals Inc | polipeptìdeos hìbridos com propriedades selecionáveis |
EP1921065B1 (de) | 2005-08-24 | 2010-10-20 | Banyu Pharmaceutical Co., Ltd. | Phenylpyridonderivat |
WO2007041052A2 (en) | 2005-09-29 | 2007-04-12 | Merck & Co., Inc. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
KR20080059233A (ko) | 2005-10-21 | 2008-06-26 | 노파르티스 아게 | 레닌 억제제, 및 항이상지질혈증제 및/또는 항비만제의조합물 |
IE20050723A1 (en) * | 2005-10-28 | 2007-05-30 | Patrick T Prendergast | Anti-mineralocorticoid therapy of infection |
TWI397417B (zh) | 2006-06-15 | 2013-06-01 | Ucb Pharma Gmbh | 具有協同抗驚厥功效之醫藥組成物 |
WO2008039327A2 (en) | 2006-09-22 | 2008-04-03 | Merck & Co., Inc. | Method of treatment using fatty acid synthesis inhibitors |
EP2072519A4 (de) | 2006-09-28 | 2009-10-21 | Banyu Pharma Co Ltd | Diarylketiminderivat |
GB0624282D0 (en) | 2006-12-05 | 2007-01-10 | Cavalla David | Treatment of cachexia |
US8106086B2 (en) | 2007-04-02 | 2012-01-31 | Msd K.K. | Indoledione derivative |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
AU2008261102B2 (en) | 2007-06-04 | 2013-11-28 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
WO2009110510A1 (ja) | 2008-03-06 | 2009-09-11 | 萬有製薬株式会社 | アルキルアミノピリジン誘導体 |
WO2009119726A1 (ja) | 2008-03-28 | 2009-10-01 | 萬有製薬株式会社 | メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体 |
EP2810951B1 (de) | 2008-06-04 | 2017-03-15 | Synergy Pharmaceuticals Inc. | Für die Behandlung von gastrointestinalen Erkrankungen, Entzündungen, Krebs und anderen Erkrankungen geeignete Agonisten von Guanylatcyclase |
AU2009257174A1 (en) * | 2008-06-09 | 2009-12-17 | Dimerix Bioscience Pty Ltd | Novel receptor hetero-dimers/-oligomers |
WO2009154132A1 (ja) | 2008-06-19 | 2009-12-23 | 萬有製薬株式会社 | スピロジアミン-ジアリールケトオキシム誘導体 |
ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
US20110124674A1 (en) | 2008-07-30 | 2011-05-26 | Hiroyuki Kishino | 5/5-or 5/6-membered condensed ring cycloalkylamine derivative |
CA2732513C (en) | 2008-08-01 | 2017-04-25 | Arca Biopharma, Inc. | Methods and compositions involving (s)-bucindolol |
CA2741125A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US8329914B2 (en) | 2008-10-31 | 2012-12-11 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
US20110243940A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Bicyclic pyranone derivatives and methods of use thereof |
US20110245209A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
GB0907350D0 (en) * | 2009-04-29 | 2009-06-10 | Myotec Therapeutics Ltd | Methods |
SG182393A1 (en) | 2010-01-14 | 2012-08-30 | Novartis Ag | Use of an adrenal hormone-modifying agent |
US20120296403A1 (en) | 2010-02-10 | 2012-11-22 | Novartis Ag | Methods and compounds for muscle growth |
JP2013520502A (ja) | 2010-02-25 | 2013-06-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体 |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
CN105001219A (zh) | 2011-02-25 | 2015-10-28 | 默沙东公司 | 用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物 |
KR20130074808A (ko) * | 2011-12-16 | 2013-07-05 | 한올바이오파마주식회사 | 스타틴계 지질저하제에 의한 근육계 부작용의 치료 또는 예방을 위한 로사르탄을 포함하는 약제학적 조성물 |
WO2014022528A1 (en) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
JP2016516004A (ja) | 2013-02-22 | 2016-06-02 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 抗糖尿病二環式化合物 |
WO2014138806A1 (en) | 2013-03-14 | 2014-09-18 | Coats Andrew J S | Oxprenolol compositions for treating cancer |
EP2970119B1 (de) | 2013-03-14 | 2021-11-03 | Merck Sharp & Dohme Corp. | Neuartige indolderivate als antidiabetika |
CA2905438A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
WO2014151200A2 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
KR102272746B1 (ko) | 2013-06-05 | 2021-07-08 | 보슈 헬스 아일랜드 리미티드 | 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법 |
EP2832357A1 (de) | 2013-07-29 | 2015-02-04 | Charité - Universitätsmedizin Berlin | Selektive AT2-Rezeptoragonisten zur Verwendung bei der Behandlung von Kachexie |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
ES2901114T3 (es) | 2014-08-29 | 2022-03-21 | Tes Pharma S R L | Inhibidores de ácido alfa-amino-beta-carboximucónico semialdehído descarboxilasa |
AU2017224965B2 (en) | 2016-02-26 | 2022-06-30 | Actimed Therapeutics Ltd | S-enantiomerically enriched compositions of beta blockers for treating muscle weakness |
AR109950A1 (es) | 2016-10-14 | 2019-02-06 | Tes Pharma S R L | INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA |
US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
US10799138B2 (en) | 2018-04-05 | 2020-10-13 | University Of Maryland, Baltimore | Method of administering sotalol IV/switch |
US11344518B2 (en) | 2018-08-14 | 2022-05-31 | AltaThera Pharmaceuticals LLC | Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame |
US11696902B2 (en) | 2018-08-14 | 2023-07-11 | AltaThera Pharmaceuticals, LLC | Method of initiating and escalating sotalol hydrochloride dosing |
US11610660B1 (en) | 2021-08-20 | 2023-03-21 | AltaThera Pharmaceuticals LLC | Antiarrhythmic drug dosing methods, medical devices, and systems |
US10512620B1 (en) | 2018-08-14 | 2019-12-24 | AltaThera Pharmaceuticals, LLC | Method of initiating and escalating sotalol hydrochloride dosing |
CA3119509A1 (en) | 2018-11-20 | 2020-05-28 | Tes Pharma S.R.L | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxxylase |
US10772869B1 (en) | 2019-07-24 | 2020-09-15 | ECI Pharmaceuticals, LLC | Pharmaceutical compositions including carvedilol and methods of using the same |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5541188A (en) * | 1987-09-15 | 1996-07-30 | The Rowett Research Institute | Therapeutic applications of beta-adrenergic agonists |
CA1337432C (en) | 1988-03-23 | 1995-10-24 | Raymond M. Xhonneux | Method of lowering the blood pressure |
US6545040B1 (en) * | 1988-03-23 | 2003-04-08 | Janssen Pharmaceutica N.V. | Method of lowering the blood pressure |
AU643487B2 (en) * | 1989-11-21 | 1993-11-18 | Sepracor, Inc. | Use of optically pure s(-) atenolol for the treatment of cardiovascular disorders |
EP0714663A3 (de) | 1994-11-28 | 1997-01-15 | Lilly Co Eli | Potenzierung von Wirkstoffresponz durch Serotonin 1A Rezeptor Antagonisten |
PT808172E (pt) | 1995-02-10 | 2003-11-28 | Searle & Co | Combinacao de inibidor da enzima de conversao da angiotensina e de antagonista de aldosterona para o tratamento de hipertrofia ventricular |
JPH0971586A (ja) | 1995-09-07 | 1997-03-18 | Yamanouchi Pharmaceut Co Ltd | 新規な二環性縮合イミダゾール誘導体 |
AUPO274596A0 (en) | 1996-10-04 | 1996-10-31 | Armstrong, Stuart Maxwell | Method for the treatment of neurological or neuropsychiatric disorders |
GB9714675D0 (en) | 1997-07-11 | 1997-09-17 | Smithkline Beecham Plc | Novel composition |
PT1121111E (pt) * | 1998-10-15 | 2010-05-17 | Imp Innovations Ltd | Compostos para o tratamento de perda de peso |
NZ519547A (en) * | 2000-01-31 | 2004-03-26 | Pfizer Prod Inc | Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of PDE4 isozymes |
WO2003065970A2 (en) * | 2001-02-20 | 2003-08-14 | Royal College Of Surgeons Ie | Treatment of fibromyalgia and related fatigue syndromes using pindolol |
AU2005283829A1 (en) | 2004-09-17 | 2006-03-23 | Neurocure Ltd | Pindolol for the treating premenstrual syndrome and premenstrual dysphoric disorder |
CN101065014A (zh) | 2004-09-23 | 2007-10-31 | 亚历山大·米哈洛 | 通过诱导逆适应调节神经递质***的方法 |
WO2006102476A2 (en) | 2005-03-21 | 2006-09-28 | Vicus Therapeutics Spe 1, Llc | Compositions and methods for ameliorating cachexia |
JP2009526087A (ja) | 2005-12-22 | 2009-07-16 | アナボレックス, インコーポレイテッド | 悪液質の予防および処置のための組成物および方法 |
JP2009528289A (ja) | 2006-02-27 | 2009-08-06 | ミシャロウ、アレクサンダー | 対抗適応を誘発することにより神経伝達物質系を調節する方法 |
US20100298243A1 (en) | 2006-11-09 | 2010-11-25 | Boehringer Ingelheim International Gmbh | Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions |
JP5627452B2 (ja) | 2007-04-24 | 2014-11-19 | アカシア ファーマ リミテッドAcacia Pharma Limited | 筋肉減少の治療に使用される薬剤の組合せ |
JP2011516412A (ja) | 2008-03-05 | 2011-05-26 | ビカス セラピューティクス,エルエルシー | 癌および粘膜炎の治療のための組成物および方法 |
-
1999
- 1999-10-15 PT PT99947762T patent/PT1121111E/pt unknown
- 1999-10-15 DE DE69942009T patent/DE69942009D1/de not_active Expired - Lifetime
- 1999-10-15 WO PCT/GB1999/003302 patent/WO2000021509A2/en active Application Filing
- 1999-10-15 DK DK99947762.3T patent/DK1121111T3/da active
- 1999-10-15 US US09/807,558 patent/US7417038B1/en not_active Expired - Fee Related
- 1999-10-15 JP JP2000575485A patent/JP2002527378A/ja active Pending
- 1999-10-15 EP EP99947762A patent/EP1121111B1/de not_active Expired - Lifetime
- 1999-10-15 AT AT99947762T patent/ATE457169T1/de active
-
2008
- 2008-08-15 US US12/192,780 patent/US7829596B2/en not_active Expired - Fee Related
-
2010
- 2010-05-10 CY CY20101100408T patent/CY1110282T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
US7829596B2 (en) | 2010-11-09 |
DK1121111T3 (da) | 2010-05-31 |
PT1121111E (pt) | 2010-05-17 |
WO2000021509A2 (en) | 2000-04-20 |
US20090023639A1 (en) | 2009-01-22 |
US7417038B1 (en) | 2008-08-26 |
WO2000021509A3 (en) | 2000-11-09 |
EP1121111A2 (de) | 2001-08-08 |
JP2002527378A (ja) | 2002-08-27 |
ATE457169T1 (de) | 2010-02-15 |
CY1110282T1 (el) | 2015-01-14 |
EP1121111B1 (de) | 2010-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69942009D1 (de) | Verbindungen für die behandlung von gewichtsverlust | |
ATE334985T1 (de) | Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe | |
AU2003268144A8 (en) | Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist | |
RU92016534A (ru) | Синергетические терапевтические композиции и способы достижения синергетического терапевтического эффекта | |
IL149890A0 (en) | Tnt-alpha antagonist and lfa-1 antagonist for treating lfa-1 or tnf-alpha mediated | |
ES2196361T3 (es) | Combinaciones terapeuticas de antagonistas de rar y agonistas de rxr. | |
DE69925024D1 (de) | Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten | |
ATE218854T1 (de) | Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin- abhängigen protein kinase | |
WO2001001972A3 (en) | SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE | |
MXPA05007381A (es) | Metodo para el tratamiento de transtornos funcionales del intestino. | |
DE602004011051D1 (de) | Verfahren zur behandlung von krankheiten mit hsp90-hemmenden mitteln in kombination mit antimetaboliten | |
ATE401913T1 (de) | Behandlung oder prävention von unplanmässigen blutungen bei frauen unter progestogenhaltiger medikation | |
ATE214272T1 (de) | Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz | |
DE69733557D1 (de) | Endothelin-antagonisten zur behandlung von herzversagen | |
TR200103418T2 (tr) | Melatoninin tedavi edici kullanımı. | |
MY126321A (en) | Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer. | |
DE60325965D1 (de) | Für die behandlung bzw. prevention von schmerzen geeignete triazaspiroverbindungen | |
HK1072012A1 (en) | 5-ht4 receptor antagonists for the treatment of heart failure | |
ATE262362T1 (de) | Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung | |
DE60017793D1 (de) | Verfahren zur vorbeugung und behandlung von beschädigung des schleimhautgewebes | |
MXPA02007454A (es) | Compuestos utiles para tratamiento o prevencion de una enfermedad mediada por el alfa-2b-adrenoceptor. | |
UA33531A (uk) | Спосіб терапії шизофренії |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |